Artificial Intelligence-Guided Endpoint Selection for Neuroprotection Trials in Glaucoma
Open Access
- 2 January 2026
- journal article
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 284, 88-100
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (EY036593)
- National Institutes of Health (EY033831)
- Glaucoma Research Foundation (Endpoints2025MedeF)
- Florida Department of Health
This publication has 25 references indexed in Scilit:
- Subretinal Gene Therapy Drug AGTC-501 for XLRP Phase 1/2 Multicenter Study (HORIZON): 24-Month Safety and Efficacy ResultsAmerican Journal of Ophthalmology, 2024
- Prediction of Visual Field Progression with Baseline and Longitudinal Structural Measurements Using Deep LearningAmerican Journal of Ophthalmology, 2024
- Visual Field Endpoints for Neuroprotective Trials: A Case for AI-Driven Patient EnrichmentAmerican Journal of Ophthalmology, 2022
- Rates of Glaucomatous Structural and Functional Change From a Large Clinical Population: The Duke Glaucoma Registry StudyAmerican Journal of Ophthalmology, 2021
- Improving the Feasibility of Glaucoma Clinical Trials Using Trend-Based Visual Field Progression End PointsOphthalmology Glaucoma, 2019
- Detection of Longitudinal Visual Field Progression in Glaucoma Using Machine LearningAmerican Journal of Ophthalmology, 2018
- Comparison of Glaucoma Progression Detection by Optical Coherence Tomography and Visual FieldAmerican Journal of Ophthalmology, 2017
- Longitudinal Changes in Quality of Life and Rates of Progressive Visual Field Loss in Glaucoma PatientsOphthalmology, 2015
- The Pathophysiology and Treatment of GlaucomaJAMA, 2014
- Patterns of glaucomatous visual field progression identified by three progression criteriaAmerican Journal of Ophthalmology, 2004